We’ve recently updated our valuation analysis.

C21 Investments Valuation

Is CXXI undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 4/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CXXI?

Other financial metrics that can be useful for relative valuation.

CXXI key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.3x
Enterprise Value/EBITDA5.1x
PEG Ration/a

Price to Earnings Ratio vs Peers

How does CXXI's PE Ratio compare to its peers?

The above table shows the PE ratio for CXXI vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average9.1x
VEXT Vext Science
CTX Crescita Therapeutics
MRV Nuvo Pharmaceuticals
XRTX XORTX Therapeutics
CXXI C21 Investments

Price-To-Earnings vs Peers: CXXI is good value based on its Price-To-Earnings Ratio (7.2x) compared to the peer average (9.1x).

Price to Earnings Ratio vs Industry

How does CXXI's PE Ratio compare vs other companies in the North American Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a62.1%

Price-To-Earnings vs Industry: CXXI is good value based on its Price-To-Earnings Ratio (7.2x) compared to the North American Pharmaceuticals industry average (16.4x)

Price to Earnings Ratio vs Fair Ratio

What is CXXI's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CXXI PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio7.2x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate CXXI's Price-To-Earnings Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of CXXI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: CXXI (CA$0.3) is trading below our estimate of fair value (CA$0.76)

Significantly Below Fair Value: CXXI is trading below fair value by more than 20%.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies